malic enzyme

Malic enzyme inhibitor ME1 (ME1) is a specific inhibitor of Malic enzyme (IC50 = 0.15 μM). Malic enzyme inhibitor ME1 reduces cell viability/metabolic activity.

KYLO-0603 is an orally active and selective THR-β agonist with an EC50 of 31.07 nM. It effectively reduces serum cholesterol and low-density lipoprotein cholesterol levels. By activating THR-β receptors, KYLO-0603 enhances the expression of THR-regulated genes like iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone-responsive (Thrsp) gene, while it inhibits the expression of inflammatory and fibrosis-related genes, including low-density lipoprotein receptor (LDL-R) gene. This compound is applicable for the study of metabolic associated steatohepatitis (MASH) and liver fibrosis.

N6-Etheno-nicotinamide dinucleotide phosphate (ε-NADP+) trisodium is a structural analog of NADP(+). It acts as an inhibitor of maize malic enzyme with a Ki value of 1.01 μM.

AS1134900 is a highly selective, non-competitive, metabotropic NADP+-dependent malic enzyme 1 (ME1) inhibitor.

Malic dehydrogenase catalyzes the reversible conversion of oxaloacetate and malate and is closely associated with the oxidation and reduction of dinucleotide coenzymes. Malic dehydrogenase serves as a fundamental enzyme in cellular metabolism and is widely utilized in research involving energy metabolism, mitochondrial function, redox homeostasis, and enzymatic reaction networks.